SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a class of antihyperglycemic agents that act by inhibiting the SGLT proteins in the proximal convoluted tubules of the kidney.1 By inhibiting this protein, SGLT-2 inhibitors limit the reabsorption of filtered sodium and glucose, thereby enhancing urinary glucose excretion, natriuresis, and improving urine output.2,3 Beyond their primary role in managing type 2 diabetes, SGLT-2 inhibitors have demonstrated significant cardiovascular benefits, including reductions in cardiovascular mortality and hospitalizations.